New shot could reduce bleeds in hemophilia a patients
NCT ID NCT07416526
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a new drug called NXT007 (Zemocimig) against standard Factor VIII treatment to prevent bleeding in people with severe or moderate hemophilia A who do not have inhibitors. About 126 participants aged 12 and older will receive either NXT007 as a shot under the skin or their usual Factor VIII infusions. The main goal is to see if NXT007 reduces the number of bleeds that need treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NXT007 (Zemocimig)
What this could lead to
If successful, NXT007 could offer a more convenient, less frequent treatment option to prevent bleeding episodes in people with hemophilia A.
What could go wrong
This is a Phase 3 trial, but results may not apply to everyone. NXT007 is a new drug, and its long-term safety and effectiveness compared to standard care are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nara Medical University Hospital
RECRUITINGKashihara-shi, Nara, 634-8522, Japan
-
Tokyo Medical University Hospital
RECRUITINGShinjuku-Ku, Tokyo, 160-0023, Japan